AGMT
  • About us
    • About us
    • Executive board
    • Partner
    • Team
    • Contact
  • Trials
    • Hodgkin Lymphoma
      • HD 21
      • AERN
      • BRESELIBET
    • Non-Hodgkin Lymphoma
      • DSHNHL_NIVEAU
      • ORACLE
      • Pola-R-ICE
    • Multiple Myeloma
      • MM-4
    • Pancreatic Cancer
      • DIsCOvER
    • COVID-19
      • INSERM_DisCoVeRy
  • Registries
    • AIHA Registry
    • aMYELOIDr
    • ARIADNE NIS
    • CLL-Registry
    • COVID-19 Registry
    • LungCA Registry
    • MBC Registry
    • NGS Registry
    • PTCL Registry
  • Events
    • Breast Cancer Talk – 2020
  • Publications
  • News
    • News Overview
    • News Archive
  • Contact
  • AAA
  • Login
  • en
    Languages
    • en English
    • de Deutsch

AGMT_COVID-19 Registry

Austrian COVID-19 Registry

Synopsis

Short title: AGMT_COVID-19 Registry

Title: Austrian COVID-19 Registry

Status: open

Start: April 2020

Coordinating Investigator: Univ. Prof. Dr. Richard Greil

NIS Number: NIS008028

ClinicalTrialsID: NCT04351529

Number of patients: 1000 (planned)

Sponsor: AGMT gemeinnützige GmbH

Design

The AGMT_COVID-19 Registry is designed as multicenter observational cohort of patients, that are tested positive for SARS-CoV-2. Data will be collected from all sites in Austria willing to participate.
Due to the non-interventional nature of the AGMT_COVID-19 registry, only routine data, which has already been recorded in the patient’s medical chart, is transferred to the eCRF. Treatment indication, the decision to offer treatment, treatment choice, dose, schedule and dose reductions/escalations, and response assessments shall be exclusively based on the risk/benefit estimation of the treating physician.

An estimated 1000 patients are expected to be included; these numbers may be revised over time as interest and demand dictates.

Objectives:

To assess the clinical and treatment patterns of patients with COVID-19.

Inclusion/Exclusion Criteria

Inclusion Criteria:

Physicians will select appropriate patients for enrollment. Appropriate patients are expected to:

  • Age >18 years
  • Positive test for SARS-CoV-2

Due to the non-interventional design of the registry there are no specific inclusion or exclusion criteria.
Participation in the registry must not interfere with diagnostic and/or therapeutic decision making.

Registries
  • Registries
    • Registry-AIHA
    • Registry-aMYELOIDr
    • Registry-ARIADNE
    • Registry-CLL
    • Registry-LungCA
    • Registry-MBC
    • Registry-NGS
    • Registry-PTCL
Arbeitsgemeinschaft medikamentöse Tumortherapie gemeinnützige GmbH
Firmensitz und Rechnungsadresse: Gentzgasse 60/21, 1180 Wien
Zweigstelle & Zustelladresse: Wolfsgartenweg 31, 5020 Salzburg
Firmenbuchnummer: FN 289548 g
UID-Nummer: ATU63467108
+43 662 640 44 12
+ 43 664 142 25 04
+43 662 640 44 14
office@agmt.at
Copyright © AGMT gemeinnützige GmbH
  • Site notice
  • Data protection declaration
  • LinkedIn AGMT